BGI Genomics
Chantal Shen is an experienced professional in the fields of genome synthesis, synthetic biology, and bioinformatics. Currently serving as the Director of the Genome Synthesis and Editing Platform at China National GeneBank since September 2016, Chantal has also held multiple key roles at BGI Shenzhen, including Head of the Unit of Synthetic Biology, project manager, and bioinformatics analyser since March 2010. Prior to these positions, Chantal worked as a financial consultant at China Merchants Bank from February to December 2009. Chantal's academic background includes a Master’s degree in Biomedical/Medical Engineering from the University of Melbourne (2009-2011) and a Bachelor of Engineering in Bioengineering and Biomedical Engineering from South China University of Technology (2004-2008).
This person is not in any offices
BGI Genomics
3 followers
BGI was founded in 1999 as a research organization to support the Human Genome Project. Over the years, BGI’s in-house research has contributed to the development of the field of Genomics in significant ways, as evidenced by a wealth of peer-reviewed publications in prestigious scientific journals. Today, BGI is actively participating in the fields of Cancer Research, Bio-sustainability and Personalized Medicine through a global network of collaborators. BGI Genomics is the world’s leading provider of genomic and proteomic services, now serving customers in more than 66 countries. We provide academic institutions, pharmaceutical companies, health care providers and other organizations with integrated genomic and proteomic services and solutions across a broad range of applications spanning basic and translational research, drug discovery, agriculture and health care. To provide these services, we operate a large network of service Laboratories in China, Hong Kong, the US and Europe. Our customers benefit from the highest level of sequencing experience in the world to support their research and drug discovery projects. Our service laboratories operate under strict internationally recognized quality systems, such as those from CAP and ISO. More recently, BGI developed and launched its own DNBseq™ sequencing technology, based on DNA Nanoball sequencing technology that was invented in our Complete Genomics research facility in Silicon Valley, California. Scientists around the world now rely on DNBseq NGS services for the highest quality data at the lowest cost.